Clinical curative effect of Pingchuan prescription combined with montelukast sodium on patients with bronchial asthma
10.12206/j.issn.2097-2024.202405035
- VernacularTitle:平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察
- Author:
Chunjuan CHEN
1
;
Zhixin ZHENG
1
;
Li LI
1
Author Information
1. Department of Pharmacy, b. Department of Pediatric Infective Diseases, Baoji Maternal and Child Health Hospital, Baoji 721000, China.
- Publication Type:Medicine&Clinical
- Keywords:
Pingchuan prescription;
montelukast sodium;
bronchial asthma;
inflammatory factor
- From:
Journal of Pharmaceutical Practice and Service
2024;42(12):524-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical curative effect of Pingchuan prescription combined with montelukast sodium on patients with bronchial asthma. Methods A total of 102 patients with bronchial asthma admitted to the hospital were enrolled between May 2022 and December 2023. According to simple randomization method, they were divided into control 1 group （montelukast sodium，n=34）, control 2 group （Pingchuan prescription，n=34） and observation group （Pingchuan prescription combined with montelukast sodium，n=51）. All patients were treated for 21 d. The clinical curative effect in the three groups was evaluated. The scores of TCM syndromes, inflammatory factors [interleukin（IL）-4, IL-17, interferon（IFN）-γ, transforming growth factor-β1（TGF-β1）, immunoglobulin（Ig）E] and scores of the test for respiratory and asthma control in kids （TRACK） in the three groups were compared before and after treatment. The adverse reactions were recorded. Results Compared with control 1 group and control 2 group, total response rate was higher in observation group （P<0.05）. After treatment, scores of TCM syndromes （wheezing due to phlegm in throat, tachypnea, choking）in observation group were lower than those in control 1 group and control 2 group （P<0.05）. After treatment, levels of IL-4, IL-17, TGF-β1 and IgE in observation group were lower than those in control 1 group and control 2 group, while IFN-γ level and TRACK score were higher than those in control 1 group and control 2 group （P<0.05）. There was no difference in adverse reactions among the three groups （P>0.05）. Conclusion Pingchuan prescription combined with montelukast sodium could improve clinical curative effect in patients with bronchial asthma, which was beneficial to alleviate inflammatory response and disease severity, with certain safety.
